Pfizer, Merck KGaA Partner with Debiopharm on Lung Cancer Drug
By
Pfizer and Merck KGaA have formed a collaboration with Debiopharm International, a Lausanne, Switzerland-based biopharmaceutical group of five companies, to evaluate the combination of Debio 1143, Debiopharm’s oral, small-molecule inhibitor…
Novartis Partners for Nanoparticle-Drug Conjugates
By
Novartis has formed a collaboration with Cerulean Pharma, a Waltham, Massachusetts-based clinical-stage company developing nanoparticle-drug conjugates (NDCs), to develop NDC product candidates combining Cerulean’s proprietary tumor-targeting technology with Novartis’ proprietary…
Allergan Gets US FTC OK for $1.7 Billion Acquisition of Tobira Therapeutics
By
Allergan has received US antitrust clearance for its proposed $1.7 billion acquisition of Tobira Therapeutics, a South San Francisco-based clinical-stage biopharmaceutical company focused on developing treatments for non-alcoholic steatohepatitis (NASH) and…